Form 4: Milestone COO Nelson Reports Share Transactions

Milestone Pharmaceuticals' Chief Operating Officer, Jeffrey Edward Nelson, reported recent acquisitions and sales of company common shares tied to equity award vestings and tax obligations.

Summary

• Jeffrey Edward Nelson, Chief Operating Officer of Milestone Pharmaceuticals Inc. (MIST), reported several transactions involving company common shares and derivative securities.
• On December 12, 2025, Nelson acquired 100,000 common shares through the vesting of a performance stock unit (PSU) award, triggered by the U.S. FDA's New Drug Application Approval Letter for Cardamyst (etripamil).
• Also on December 12, 2025, Nelson acquired 100,000 employee stock options with an exercise price of $1.74, which will vest 50% on June 12, 2026, and 50% on December 12, 2026.
• On December 15, 2025, Nelson sold 58,007 common shares at a weighted average price of $2.32 to cover income tax liabilities incurred from the PSU vesting.
• On January 26, 2026, Nelson acquired 20,100 common shares from the vesting of restricted stock unit (RSU) awards.
• On January 26, 2026, Nelson sold 12,245 common shares at a weighted average price of $1.93 to cover income tax liabilities from the RSU vesting.
• Following these transactions, Nelson beneficially owns 49,848 direct common shares and 60,300 derivative restricted stock units.

Sentiment

Score: 7

Explanation: The filing primarily reports routine insider transactions related to equity compensation. The positive aspect is the vesting of PSUs tied to a significant FDA approval, which is a strong positive for the company's product development. The sales are for tax purposes, which is neutral. The acquisition of new options is also positive for future alignment.

Positives

• Vesting of 100,000 performance stock units (PSUs) was triggered by the U.S. Food and Drug Administration's New Drug Application Approval Letter for Cardamyst (etripamil), indicating a significant regulatory milestone for the company.
• Acquisition of 100,000 employee stock options with an exercise price of $1.74, providing future potential upside for the COO and aligning interests with company performance.

Negatives

• Sales of 58,007 common shares at $2.32 and 12,245 common shares at $1.93 were conducted as 'sell-to-cover' transactions, reducing the COO's direct share ownership.
• The sale price for the second transaction ($1.93) was lower than the first ($2.32).

Risks

• The vesting of future employee stock options and restricted stock units is subject to the Reporting Person continuing to provide service through each such date.

Future Outlook

Future vesting of employee stock options and restricted stock units is scheduled through December 2026 and January 2029, respectively, contingent on the COO's continued service. The initial PSU vesting was tied to the FDA approval of Cardamyst (etripamil), suggesting a positive development for the company's product pipeline.

Industry Context

This Form 4 filing details routine insider transactions related to equity compensation and tax obligations. The key industry context is the successful FDA approval of Cardamyst (etripamil), which triggered a significant performance stock unit vesting. This approval is a major milestone for Milestone Pharmaceuticals, a biopharmaceutical company focused on cardiovascular diseases, and indicates progress in bringing new therapies to market. Such regulatory successes are critical for growth in the pharmaceutical industry.

Comparison to Industry Standards

• The 'sell-to-cover' mechanism for tax liabilities is a standard practice for executives receiving equity compensation across various industries, including pharmaceuticals, to manage tax obligations without requiring personal cash outlays.
• The grant of performance stock units (PSUs) tied to a specific regulatory milestone, such as FDA approval, is a common and effective incentive structure in the biopharmaceutical sector, aligning executive compensation with critical product development achievements.
• The vesting schedules for employee stock options (50% on June 12, 2026, and 50% on December 12, 2026) and restricted stock units (1/4th annually from January 26, 2026, to January 26, 2029) are typical multi-year vesting schedules designed to promote long-term retention and alignment with shareholder interests, consistent with industry norms for executive compensation.

Stakeholder Impact

• Shareholders: The FDA approval of Cardamyst (etripamil) is a positive development, potentially increasing the value of Milestone Pharmaceuticals' shares. The insider sales, while for tax purposes, slightly reduce the COO's direct ownership.
• Employees: The equity awards (PSUs, RSUs, options) serve as incentives for key management, aligning their interests with company performance and retention.
• Customers/Patients: The FDA approval of Cardamyst (etripamil) indicates a new treatment option may become available, benefiting patients.

Next Steps

• Continued vesting of 50% of employee stock options on June 12, 2026, and 50% on December 12, 2026.
• Continued vesting of 1/4th of the RSU award on January 26, 2027, January 26, 2028, and January 26, 2029.

Key Dates

Recommendation

This Form 4 primarily details routine insider transactions related to equity compensation and tax obligations. The underlying trigger for the performance stock unit vesting, the FDA approval of Cardamyst (etripamil), is a significant positive for Milestone Pharmaceuticals, indicating successful product development and potential future revenue streams. However, the sales are for tax purposes and do not reflect a change in management's fundamental view of the company. The acquisition of new options also aligns the COO's interests with future growth. Given the positive regulatory milestone but the routine nature of the sales, a 'hold' recommendation is appropriate, awaiting further operational and financial updates related to Cardamyst's commercialization.

Keywords

Milestone Pharmaceuticals, MIST, Jeffrey Edward Nelson, COO, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Performance Stock Units, FDA Approval, Cardamyst, etripamil, Sell-to-Cover, Equity Awards